CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Area of Science:

• Regenerative Medicine
• Gene Therapy
• Molecular Biology

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by mutations in the dystrophin gene.
• Current treatments for DMD are limited, highlighting the need for innovative therapeutic strategies.
• Restoring dystrophin expression is a key goal for DMD treatment.

Purpose of the Study:

• To develop a combined CRISPR/Cas9 and induced pluripotent stem cell (iPSC) approach to restore dystrophin expression in muscle progenitor cells (MPCs).
• To assess the feasibility of using gene editing to correct the genetic defect in DMD.
• To generate functional MPCs for potential DMD therapies.

Main Methods:

• Established a non-integrating iPSC line from Dmd^mdx mouse dermal fibroblasts using a Sendai vector.
• Employed CRISPR/Cas9 gene editing to delete the mutated exon23 of the dystrophin gene via non-homologous end joining.
• Differentiated iPSCs into MPCs using doxycycline-induced MyoD expression.

Main Results:

• Successfully restored dystrophin protein expression in iPSC-derived MPCs through CRISPR/Cas9-mediated gene editing.
• Validated exon23 depletion in iPSC colonies using PCR.
• Demonstrated the differentiation of edited iPSCs into MPCs with restored dystrophin.

Conclusions:

• The study presents a feasible CRISPR/Cas9 deletion strategy to restore dystrophin expression in iPSC-derived MPCs.
• This combined approach holds significant promise for developing future therapeutic strategies for Duchenne muscular dystrophy.
• Non-integrating iPSC technology combined with gene editing offers a potential pathway for autologous cell-based therapies for DMD.